8-K: Twist Bioscience Reports Strong Q2 Results, Raises Full Year Guidance

Twist Bioscience announced a 25% increase in revenue and a 45% increase in orders for the second quarter of fiscal year 2024, along with an improved full-year outlook.

Summary

• Twist Bioscience reported a strong second quarter for fiscal year 2024, with revenue reaching $75.3 million, a 25% increase compared to $60.2 million in the same period last year.
• Orders also saw significant growth, increasing by 45% to $93.2 million from $64.2 million in the second quarter of fiscal year 2023.
• The company has raised its full-year revenue guidance to a range of $300 million to $304 million and gross margin guidance to 41.5% to 42.0%.
• Gross margin improved significantly from 31% in Q2 FY23 to 41% in Q2 FY24.
• Net cash used in operating activities for the first six months of fiscal year 2024 was $42.4 million, a substantial improvement from $98.4 million in the same period of 2023.
• The company is aiming for a gross margin of over 50% by the end of fiscal year 2025.
• The net loss for the quarter was $45.5 million, or $0.79 per share, compared to a net loss of $59.2 million, or $1.04 per share, in the same quarter of the previous year.
• Adjusted EBITDA for the quarter was -$26.8 million, compared to -$45.5 million in the same period last year.
• As of March 31, 2024, Twist had $293.3 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue and order growth, improved gross margins, and increased full-year guidance. The company is making progress towards profitability, which is encouraging for investors.

Positives

• Revenue and orders both experienced substantial year-over-year growth.
• The company has increased its full-year revenue and gross margin guidance.
• Gross margin improved significantly year-over-year.
• Net cash used in operating activities has decreased substantially.
• The company launched several new products and expanded its customer base.
• The company is making progress towards its goal of achieving profitability.

Negatives

• Biopharma revenue decreased to $4.7 million in Q2 FY24 from $7.0 million in Q2 FY23.
• The company reported a net loss of $45.5 million for the quarter.
• The company is still operating at a loss, with an adjusted EBITDA of -$26.8 million for the quarter.

Risks

• The company's ability to achieve profitability depends on the success of its existing and new products.
• The synthetic biology industry is subject to rapidly changing technologies and intense competition.
• The company faces risks related to supply chain disruptions and third-party claims of patent infringement.
• The company's proprietary rights may not be sufficient to protect its technologies.

Future Outlook

Twist Bioscience has increased its full-year revenue guidance to $300-$304 million and gross margin guidance to 41.5-42.0%. The company expects to achieve a gross margin of over 50% by the end of fiscal year 2025.

Management Comments

• Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, stated that this was another very strong quarter for Twist with both revenue and orders increasing.
• Dr. Leproust also noted the company's focus on its path to profitability and the improvement in cash flow from operating activities.

Industry Context

The announcement reflects the growing demand for synthetic DNA and NGS tools in various industries, including healthcare, agriculture, and research. Twist's focus on innovation and product development positions it well in the competitive synthetic biology market.

Comparison to Industry Standards

• Compared to companies like Ginkgo Bioworks, which also operates in the synthetic biology space, Twist's revenue growth of 25% is a strong indicator of market traction.
• The improvement in gross margin from 31% to 41% is a positive sign, as many companies in this sector struggle with profitability.
• The increase in orders by 45% suggests strong future revenue potential, which is a key metric for investors in high-growth technology companies.
• While companies like Illumina dominate the NGS market, Twist's focus on differentiated products and high-throughput solutions positions it as a strong competitor in specific niches.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may be encouraged by the company's growth and progress towards profitability.
• Customers will benefit from the company's new product launches and continued innovation.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will continue to focus on increasing revenue and improving gross margins.
• Twist will continue to develop and launch new products.
• The company will host a conference call to discuss the results and provide an update on the business.

Key Dates

Keywords

synthetic biology, genomics, DNA synthesis, next-generation sequencing, NGS, biopharma, gross margin, revenue, EBITDA, orders